Identifying priority medicines policy issues for New Zealand: a general inductive study

摘要: Objectives To identify priority medicines policy issues for New Zealand. Setting Stakeholders from a broad range of healthcare and institutions including primary, secondary tertiary care. Participants Exploratory, semistructured interviews were conducted with 20 stakeholders throughout Primary outcome measures The digitally recorded, transcribed coded into INVIVO 10, then compared grouped similarity theme. Perceptions, experiences opinions regarding Zealand9s recorded. Results A large proportion appeared to be unaware (NZ) policy. In general, the was considered offer consistency guide decision-making. context Pharmaceutical Management Agency9s (PHARMAC9s) fixed budget procuring subsidising medicines, there reasonable satisfaction available—rare disorder being clear exception. Concerns raised by whom how decisions are made whether desired health outcomes measured. Other concerns included inconsistencies in evidence across technologies. Despite attempts improve situation, lower socioeconomic groups (including rural residents) Māori Pacific ethnicities people rare disorders face challenges regards accessing medicines. barriers include, convenience affordability prescribers increase prescription fees NZ$3 NZ$5. related PHARMAC Zealand included: constraining budget; non-transparency in-house analysis; lack recommendations between Pharmacology Therapeutics Advisory Committee. Constraints inefficiencies also exist submission process access high-cost Conclusions results suggest availability subsidised However, some major include vulnerable groups, increasing costs demand new prescribers, budgetary constraints, cultural literacy, patient requirement gaining subsidy